1Anderson GD, Gidal BE, Messenheimer JA, et al. Time course of lamotrigine de induction: impact of step wise with- drawal of carbamazepine or phenytoin [J]. Epilepsy Res, 2002, 49 (3): 211-217.
3Zhang S, Wang I., Lu W. Population pharmacokinetics of lam- otrigine in Chinese children with epilepsy [J]. Zhongguo Dang Dai Er Ke Za Zhi, 2008, 10 (2): 105-109.
4Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic in- teraction o levetiracetam on carbamazepine, valproic acid, topiranmte, and lamotrigine in children with epilepsy [J]. Epi- lepsia, 2007, 48 (11): 2111-2115.
5Rivas N, Buelga DS, Elger CE, et al. Population pharmacoki- netics of lamotrigine with data from therapeutic drug monito- ring in German and Spanish patients with epilepsy [J] Ther DrugMonit, 2008, 30 (4): 483 489.
6Punyawudho B, Ramsay RE, Macias FM, et al. Population pharmacokinetics of lamotrigine in elderly patients [J]. J Clin Pharmacol, 2008, 48 (4): 455 463.
7Milovanovic JR, Jankovic SM. Population pharmacokinetics of lamotrigine in patients with epilepsy [J]. Int J Clin Pharmacol Ther, 2009, 47 (12): 752-760.
8Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady state pharmaeokinetics of earbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiaga- bine [J]. Epilepsia, 2011, 52 (2): 405-409.
9Rowland A, Elliot DJ, Williams JA, et al. In vitro character ization of lamotrigine N2-glucuronidation and the lamotrigine- valproic acid interaction[J]. Drug Metab Dispos, 2006, 34 (6) : 1055-1062.
10Martin AC, Besag FM, Berry DJ, et al. The effect of lam- otrigine on valproic acid concentrations [J]. Curr Drug Saf, 2011, 6 (1).. 23-29.
4GIDAL B E, SHETH R, PARNELL J, et al. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics:implications for conversion to lam- otrigine monotherapy [ J ]. Epilepsy Research, 2003,57 (2 -3) :85 -93.
5CONTIN M, BALBONI M, ERICA C T, et al. Simulta- neous liquid chromatographic determination of lam- otrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy[J]. Jour- nal of Chromatography B, 2005,828 ( 1 - 2 ) : 113 - 117.
7Majkowski J, Bourgeois B, Patsalos P, et al. Antiepileptic drugs combination therapy and interactions [M]. New York: Cambridge University Press, 2005 : 393.
8Serralheiro A, Alves G, Fortuna A, et al. First HPLC-UV method for rapid and simultaneous quantification of phenobar- bital, primidone, phenytoin, carbamazepine, carbamazepi- ne-10, ll-epoxide, 10, ll-trans-dihydroxy-10, ll-dihydro- carbamazepine, lamotrigine, oxcarbazepine and licarbazepine in human plasma [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 925: 1-9.
9Hotha KK, Kumar SS, Bharathi DV, et al. Rapid and sen- sitive LC-MS/MS method for quantification of lamotrigine in human plasma: application to a human pharmacokinetic study [J]. Biomed Chromatogr, 2012, 26 (4) : 491-496.
10Shah H J, Subbaiah G, Patel DM, et al. Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS [J]. J Chromatogr Sci, 2010, 48 ( 5 ) : 375-381.
